Literature DB >> 32767452

Prior distributions for variance parameters in a sparse-event meta-analysis of a few small trials.

Konstantinos Pateras1, Stavros Nikolakopoulos1, Kit C B Roes2.   

Abstract

In rare diseases, typically only a small number of patients are available for a randomized clinical trial. Nevertheless, it is not uncommon that more than one study is performed to evaluate a (new) treatment. Scarcity of available evidence makes it particularly valuable to pool the data in a meta-analysis. When the primary outcome is binary, the small sample sizes increase the chance of observing zero events. The frequentist random-effects model is known to induce bias and to result in improper interval estimation of the overall treatment effect in a meta-analysis with zero events. Bayesian hierarchical modeling could be a promising alternative. Bayesian models are known for being sensitive to the choice of prior distributions for between-study variance (heterogeneity) in sparse settings. In a rare disease setting, only limited data will be available to base the prior on, therefore, robustness of estimation is desirable. We performed an extensive and diverse simulation study, aiming to provide practitioners with advice on the choice of a sufficiently robust prior distribution shape for the heterogeneity parameter. Our results show that priors that place some concentrated mass on small τ values but do not restrict the density for example, the Uniform(-10, 10) heterogeneity prior on the log(τ2 ) scale, show robust 95% coverage combined with less overestimation of the overall treatment effect, across varying degrees of heterogeneity. We illustrate the results with meta-analyzes of a few small trials.
© 2020 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bayesian; heterogeneity; meta-analysis; rare diseases; rare events

Year:  2020        PMID: 32767452      PMCID: PMC7818503          DOI: 10.1002/pst.2053

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  29 in total

1.  Small studies are more heterogeneous than large ones: a meta-meta-analysis.

Authors:  Joanna IntHout; John P A Ioannidis; George F Borm; Jelle J Goeman
Journal:  J Clin Epidemiol       Date:  2015-04-02       Impact factor: 6.437

2.  Rare disease policies to improve care for patients in Europe.

Authors:  Charlotte Rodwell; Ségolène Aymé
Journal:  Biochim Biophys Acta       Date:  2015-02-25

3.  Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

Authors:  Michael J Bradburn; Jonathan J Deeks; Jesse A Berlin; A Russell Localio
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

4.  Bayesian estimation in random effects meta-analysis using a non-informative prior.

Authors:  Olha Bodnar; Alfred Link; Barbora Arendacká; Antonio Possolo; Clemens Elster
Journal:  Stat Med       Date:  2016-10-28       Impact factor: 2.373

5.  Bayesian robustness in meta-analysis for studies with zero responses.

Authors:  F J Vázquez; E Moreno; M A Negrín; M Martel
Journal:  Pharm Stat       Date:  2016-02-23       Impact factor: 1.894

6.  Bayesian Estimation and Testing in Random Effects Meta-analysis of Rare Binary Adverse Events.

Authors:  Ou Bai; Min Chen; Xinlei Wang
Journal:  Stat Biopharm Res       Date:  2015-10-23       Impact factor: 1.452

7.  Meta-analysis of rare binary events in treatment groups with unequal variability.

Authors:  Lie Li; Xinlei Wang
Journal:  Stat Methods Med Res       Date:  2017-07-31       Impact factor: 3.021

Review 8.  Intravenous immunoglobulin for multifocal motor neuropathy.

Authors:  I N van Schaik; L H van den Berg; R de Haan; M Vermeulen
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

9.  Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews.

Authors:  Rebecca M Turner; Jonathan Davey; Mike J Clarke; Simon G Thompson; Julian Pt Higgins
Journal:  Int J Epidemiol       Date:  2012-03-29       Impact factor: 7.196

10.  Meta-analysis of few small studies in orphan diseases.

Authors:  Tim Friede; Christian Röver; Simon Wandel; Beat Neuenschwander
Journal:  Res Synth Methods       Date:  2016-06-30       Impact factor: 5.273

View more
  3 in total

Review 1.  Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.

Authors:  Moreno Ursino; Nigel Stallard
Journal:  Int J Environ Res Public Health       Date:  2021-01-24       Impact factor: 3.390

2.  Prior distributions for variance parameters in a sparse-event meta-analysis of a few small trials.

Authors:  Konstantinos Pateras; Stavros Nikolakopoulos; Kit C B Roes
Journal:  Pharm Stat       Date:  2020-08-06       Impact factor: 1.894

3.  Combined assessment of early and late-phase outcomes in orphan drug development.

Authors:  Konstantinos Pateras; Stavros Nikolakopoulos; Kit C B Roes
Journal:  Stat Med       Date:  2021-04-04       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.